Contrasting MyoKardia (MYOK) and Ocata Therapeutics (OCAT)
Ocata Therapeutics (NASDAQ: OCAT) and MyoKardia (NASDAQ:MYOK) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and profitability.
Institutional and Insider Ownership
42.9% of MyoKardia shares are owned by institutional investors. 46.1% of MyoKardia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of recent recommendations for Ocata Therapeutics and MyoKardia, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
MyoKardia has a consensus target price of $48.25, indicating a potential upside of 4.55%. Given MyoKardia’s higher possible upside, analysts clearly believe MyoKardia is more favorable than Ocata Therapeutics.
Earnings & Valuation
This table compares Ocata Therapeutics and MyoKardia’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|MyoKardia||$43.35 million||37.77||-$18.78 million||($0.69)||-66.88|
Ocata Therapeutics has higher revenue, but lower earnings than MyoKardia.
This table compares Ocata Therapeutics and MyoKardia’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
MyoKardia beats Ocata Therapeutics on 8 of the 8 factors compared between the two stocks.
About Ocata Therapeutics
Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company’s advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.
MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.
Receive News & Ratings for Ocata Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocata Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.